Kenalog is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned.

Triamcinolone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Ttriamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.

The revenue for Kenalog is expected to reach a total of $107m through 2031. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Kenalog NPV Report.

Kenalog is currently owned by Bristol-Myers Squibb.

Kenalog Overview

Triamcinolone acetonide (Kenalog, Tricortone, Omicilon-A) is a corticosteroid, acts as anti-inflammatory, anti-pruritic and vasoconstrictive agent. It is formulated as ointment, lotion and cream, spray for topical application, It is also formulated in the form of injectable suspension for intradermal, intramuscular, intraarticular, intrabursal, intralesional and intrasynovial route of administration. Kenalog is indicated in treatment of asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice, synthetic analogs may be used in conjunction with mineralocorticoids where applicable, in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis, regional enteritis and ulcerative colitis, acquired (autoimmune) hemolytic anemia, diamond-blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy, for the palliative management of leukemias and lymphomas, acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury, sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus, berylliosis, fulminating or diss eminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis, as adjunctive therapy for short- term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis,  psoriatic arthritis, rheuma toid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus, the intra-articular or so ft tissue administration of kenalog-40 injection is indicated as adjunctive therapy for short-term administration (to tide the pati ent over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.  The intra- articular or soft tissue administration of Kenalog -10 Injection) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosy novitis, epicondy litis, rheumatoid arthritis, synovitis, or osteoarthritis and the intralesional administration of Kenalog -10 Injection is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Kenalog -10 Injection may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). Kenalog Spray is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Kenalog in orabase (triamcinolone acetonide dental paste, usp), 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. Kenalog is indicated for Chronic urticative gingivitis, refractory stomatitis with erosion or ulcer and Glossitis

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.

Quick View – Kenalog

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Kenalog
Administration Pathway
  • Buccal
  • Dental
  • Intraarticular
  • Intrabursal
  • Intradermal
  • Intralesional
  • Intramuscular
  • Intrasynovial
  • Oral
  • Topical
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Hormonal Disorders
  • Immunology
  • Infectious Disease
  • Mouth and Dental Disorders
  • Musculoskeletal Disorders
  • Nutritional Disorders
  • Oncology
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.